Mean change in X-ray assessments from baseline to week 156 (mTSS score, erosion score and JSN score—evaluable cases, observed data)
| X-ray measurement* | Secukinumab 10 mg/kg IV→150 mg SC(N=161) | Secukinumab 10 mg/kg IV→75 mg SC(N=147) | |
| Overall | |||
| No of patients evaluated | 128 | 123 | |
| mTSS score | Baseline | 16.9±34.52 | 16.3±32.30 |
| Change† | 1.9±8.49 | 2.0±6.44 | |
| Erosion score | Baseline | 8.1±16.88 | 7.7±14.63 |
| Change† | 1.1±5.31 | 1.0±3.57 | |
| JSN score | Baseline | 8.8±18.36 | 8.6±18.43 |
| Change† | 0.8±3.54 | 1.0±3.42 | |
| Anti-TNF-naïve patients | (N=120) | (N=110) | |
| No of patients evaluated | 100 | 94 | |
| mTSS score | Baseline | 13.1±28.35 | 12.5±30.80 |
| Change† | 1.1±4.49 | 1.4±5.29 | |
| Erosion score | Baseline | 6.7±14.67 | 5.8±13.80 |
| Change† | 0.7±3.66 | 0.7±2.80 | |
| JSN score | Baseline | 6.4±14.30 | 6.7±17.58 |
| Change† | 0.4±1.16 | 0.7±2.78 | |
| Anti-TNF-experienced patients | (N=41) | (N=37) | |
| No of patients evaluated | 28 | 29 | |
| mTSS score | Baseline | 30.5±49.09 | 28.5±34.51 |
| Change† | 5.1±15.88 | 4.1±9.07 | |
| Erosion score | Baseline | 13.3±22.72 | 13.8±15.81 |
| Change† | 2.7±8.96 | 2.2±5.25 | |
| JSN score | Baseline | 17.2±27.21 | 14.8±20.08 |
| Change† | 2.4±7.11 | 1.8±4.93 |
Values are as mean±SD.
*Observed data.
†Change from baseline to week 156. Only patients with a value at each time point are presented.
IV, intravenous; JSN, joint space narrowing; mTSS, van der Heijde modified total Sharp score; N, total number of patients in specified group; SC, subcutaneous; TNF, tumour necrosis factor.